Expression of ISL1 and its partners in prostate cancer progression and neuroendocrine differentiation
Author:
Funder
Prostate Cancer Canada
Prostate Cancer Foundation
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s00432-021-03634-2.pdf
Reference25 articles.
1. Abou-Ouf H, Alshalalfa M, Takhar M et al (2018) Validation of a 10-gene molecular signature for predicting biochemical recurrence and clinical metastasis in localized prostate cancer. J Cancer Res Clin Oncol 144:883–891
2. Agaimy A, Erlenbach-Wunsch K, Konukiewitz B et al (2013) ISL1 expression is not restricted to pancreatic well-differentiated neuroendocrine neoplasms, but is also commonly found in well and poorly differentiated neuroendocrine neoplasms of extrapancreatic origin. Mod Pathol 26:995–1003
3. Akamatsu S, Wyatt AW, Lin D et al (2015) The placental gene PEG10 promotes progression of neuroendocrine prostate cancer. Cell Rep 12:922–936
4. Bhanvadia RR, VanOpstall C, Brechka H et al (2018) MEIS1 and MEIS2 expression and prostate cancer progression: a role For HOXB13 binding partners in metastatic disease. Clin Cancer Res 24:3668–3680
5. Bismar TA, Alshalalfa M, Petersen LF et al (2014) Interrogation of ERG gene rearrangements in prostate cancer identifies a prognostic 10-gene signature with relevant implication to patients’ clinical outcome. BJU Int 113:309–319
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The interplay between autophagy and ferroptosis presents a novel conceptual therapeutic framework for neuroendocrine prostate cancer;Pharmacological Research;2024-05
2. Single-Cell Transcriptome Analysis of Small Cell Neuroendocrine Carcinoma of the Endometrium Reveals ISL1 as a Potential Biomarker for Diagnosis and Treatment;Frontiers in Bioscience-Landmark;2024-03-13
3. The benign nature and rare occurrence of cardiac myxoma as a possible consequence of the limited cardiac proliferative/ regenerative potential: a systematic review;BMC Cancer;2023-12-18
4. Addressing the need for more therapeutic options in neuroendocrine prostate cancer;Expert Review of Anticancer Therapy;2023-02-01
5. The benign nature and rare occurrence of cardiac myxoma as a possible consequence of the limited cardiac proliferative/ regenerative potential: a systematic review;2022-11-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3